References | Year | Country | Design | Treatment | Mean age(years) | Case(hip) | Inclusion criteria | Follow-up (months) | Outcomes |
---|---|---|---|---|---|---|---|---|---|
Jayankura et al. [10] | 2023 | Belgium | RCT | OB | 46 | 23 | ARCO I–II | 24 | Progress, THA |
 |  |  |  | CD | 45 | 26 |  |  |  |
Wan et al. [9] | 2022 | China | RCT | FFG | 29.8 | 45 | ARCO II | 36 | HHS, progress, THA |
 |  |  |  | VBG | 28.8 | 46 |  |  |  |
 |  |  |  | ABG | 30.5 | 45 |  |  |  |
 |  |  |  | BMG | 30.5 | 46 |  |  |  |
Zhang et al. [19] | 2022 | China | RCT | FFG | 34.3 | 29 | ARCO II | 24 | HHS, progress, THA |
 |  |  |  | VBG | 34.4 | 30 |  |  |  |
Park et al. [12] | 2022 | Korea | RCT | BMG | 49.3 | 10 | Ficat I–II | 36 | HHS, progress, THA |
 |  |  |  | CD | 55.6 | 10 |  |  |  |
Aggarwal et al. [18] | 2021 | India | RCT | PRP | 35.2 | 25 | ARCO I–II | 12 | Progress, THA |
 |  |  |  | CD | 38.2 | 28 |  |  |  |
Li et al. [7] | 2021 | China | RCT | BMAC | 35.4 | 22 | Ficat I–IV | 24 | HHS, progress, THA |
 |  |  |  | BMG | 39.4 | 29 |  |  |  |
Li et al. [22] | 2020 | China | RCT | ABG | 38.2 | 20 | Ficat II–III | 24 | Progress, THA |
 |  |  |  | BMAC + ABG | 34.1 | 21 |  |  |  |
Hauzeur et al. [8] | 2020 | Belgium | RCT | BMAC | 50 | 26 | ARCO I–II | 36 | Progress, THA |
 |  |  |  | OB | 51 | 27 |  |  |  |
Hu et al. [4] | 2018 | China | RCT | CD | 40.3 | 65 | ARCO I–II | 24 | HHS, progress |
 |  |  |  | FFG | 40.8 | 65 |  |  |  |
Lin et al. [17] | 2018 | China | RCT | BMG | 31.5 | 16 | ARCO II–III | 36 | HHS, progress, THA |
 |  |  |  | ABG | 32.6 | 16 |  |  |  |
Cao et al. [20] | 2017 | China | RCT | VBG | 31 | 27 | ARCO I–III | 36 | HHS, progress, THA |
 |  |  |  | CD |  | 27 |  |  |  |
Li et al. [21] | 2016 | China | RCT | ABG | 36.5 | 23 | Ficat I–II | 24 | HHS, progress, THA |
 |  |  |  | VBG |  | 24 |  |  |  |
Zhao et al. [23] | 2016 | China | RCT | ABG | 33 | 25 | ARCO II–III | 12 | HHS, progress |
 |  |  |  | BMG + VBG | 30 | 23 |  |  |  |
Pepke et al. [11] | 2016 | Germany | RCT | BMAC | 44.5 | 14 | ARCO II | 24 | HHS, progress, THA |
 |  |  |  | CD | 44.3 | 11 |  |  |  |
Tabatabaee et al. [24] | 2015 | Iran | RCT | BMAC | 29.1 | 14 | ARCO I–III | 24 | Progress, THA |
 |  |  |  | CD |  | 14 |  |  |  |
Mao et al. [13] | 2015 | China | RCT | BMAC: + BMG | 34.6 | 48 | ARCO I–III | 36 | HHS, progress, THA |
 |  |  |  | BMG | 36.1 | 41 |  |  |  |
Ma et al. [5] | 2014 | China | RCT | ABG | 34.8 | 24 | Ficat I–III | 24 | Progress, THA |
 |  |  |  | BMAC + ABG | 35.6 | 25 |  |  |  |
Zhao et al. [14] | 2012 | China | RCT | CD | 33.8 | 44 | ARCO I–II | 24 | HHS, progress, THA |
 |  |  |  | BMAC | 32.7 | 53 |  |  |  |